http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113662952-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 |
| filingDate | 2021-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113662952-B |
| titleOfInvention | A compound dry powder inhaler for treating idiopathic pulmonary fibrosis and its application |
| abstract | The application provides a compound dry powder inhaler, comprising baicalin, ambroxol hydrochloride, L-leucine and phosphate, based on the mass of the compound dry powder inhaler, L-leucine accounts for 0-50%, phosphoric acid Salt accounts for 15-35%, and the total mass of baicalin and ambroxol hydrochloride accounts for 15-85%, wherein the mass ratio of baicalin and ambroxol hydrochloride is 1:(0.2-2); the compound dry powder inhalation Dv90≤5μm. The combination of baicalin and ambroxol hydrochloride can effectively reduce the inflammation and oxidative damage of lung tissue, relieve pulmonary edema and histopathological changes, and reduce pulmonary dysfunction and fibrosis; The half-life of the drug in plasma and the residence time in the body can improve the bioavailability of the drug in the lung tissue, reduce the clearance rate of the drug in the lung tissue, and prolong the residence time of the drug in the lung, which is conducive to the full play of the drug in the lung tissue effect. |
| priorityDate | 2021-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 251.